Data Published in Neurology Showed That Higher Dose of Copaxone Increased Efficacy in Relapsing-Remitting Multiple Sclerosis (RRMS)
JERUSALEM--(BUSINESS WIRE)--Apr 17, 2007 - A 9-month, randomized, double-blind, parallel-group Phase II study of 90 patients comparing a 40 mg dose of Copaxone given daily to the currently approved Copaxone 20 mg dose showed a 38 percent greater reduction in inflammatory disease activity as measured by magnetic resonance images (MRI) of the brain.
New One-Year Pharmacoeconomic Study Shows Avonex is Cost-Effective Relative to Other Interferon Therapies for Multiple Sclerosis
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr 13, 2007 - Biogen Idec Inc. (NASDAQ: BIIB) announced today that one-year data presented at the Academy of Managed Care Pharmacy's (AMCP) 2007 Annual Meeting show that Avonex (Interferon beta-1a) is a cost-effective therapy in multiple sclerosis (MS) when compared to other interferon beta treatments.
JERUSALEM--(BUSINESS WIRE)--Apr 17, 2007 - A 9-month, randomized, double-blind, parallel-group Phase II study of 90 patients comparing a 40 mg dose of Copaxone given daily to the currently approved Copaxone 20 mg dose showed a 38 percent greater reduction in inflammatory disease activity as measured by magnetic resonance images (MRI) of the brain.
New One-Year Pharmacoeconomic Study Shows Avonex is Cost-Effective Relative to Other Interferon Therapies for Multiple Sclerosis
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr 13, 2007 - Biogen Idec Inc. (NASDAQ: BIIB) announced today that one-year data presented at the Academy of Managed Care Pharmacy's (AMCP) 2007 Annual Meeting show that Avonex (Interferon beta-1a) is a cost-effective therapy in multiple sclerosis (MS) when compared to other interferon beta treatments.
posted by Bill at 8:34 AM
0 Comments:
Post a Comment
<< Home